p ikkβ  (Proteintech)

Journal: ACS Omega

Article Title: Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification

doi: 10.1021/acsomega.5c01225

Figure Lengend Snippet: Western blot analysis results. (A–C) Representative images of Western blot analysis of p38 MAPK, IKKβ, and NF-κB p65. (D–F) Relative phosphorylation levels of p38 MAPK, IKKβ, and NF-κB p65. Isotanshinone II dose-dependently inhibits phosphorylation of p38 MAPK, IKKβ, and NF-κB p65 in TGF-β1-induced LX-2 cells. Data represent mean ± SD ( n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 vs the TGF-β group.

Article Snippet: Membranes were blocked with 5% skim milk for 2 h and incubated overnight at 4 °C with the following primary antibodies: polyclonal rabbit antihuman TGF-β1 (1:1000, Boster Biological Technology, Wuhan, China), GAPDH (1:20,000, Boster Biological Technology, Wuhan, China), p38 MAPK (1:1000, Boster Biological Technology, Wuhan, China), p-p38 MAPK (1:1000, Boster Biological Technology, Wuhan, China), IKKβ (1:1000, Boster Biological Technology, Wuhan, China), p -IKKβ (1:2000, ABclonal, Wuhan, China), NF-κB (1:1000, Boster Biological Technology, Wuhan, China), and phospho–NF–κB p65(1:2000, Cell Signaling Technology, Danvers, MA, USA).

Techniques: Western Blot, Phospho-proteomics

Journal: Journal of cachexia, sarcopenia and muscle

Article Title: Nuciferine Attenuates Cancer Cachexia-Induced Muscle Wasting in Mice via HSP90AA1.

doi: 10.1002/jcsm.13777

Figure Lengend Snippet: FIGURE 5 | NF inhibited inflammation response of muscle via HSP90AA1/NF-κB pathway in LLC tumour-bearing mice. (a) Representative Western blots showing the expression of HSP90AA1, p-IKKβ, p-NF-κB, IL-6 and TNF-α in the gastrocnemius muscle. (b–f) Relative protein levels in the experiments shown in A. The data were shown as the mean ± SD, n = 5. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

Article Snippet: Following the blocking process, the membranes were subjected to overnight incubation at 4°C with homologous primary antibodies aimed at GAPDH (1:40 000, Proteintech, 60004- 1- Ig, Wuhan, China), AKT(1:1000, Cell Signaling Technology, 92772S, MA, United States), p- AKT (Ser473,1:1000, ABclonal, AP0140,Wuhan, China), p- mTOR (Ser2448,1:1000, Cell Signaling Technology, 5536T, MA, United States), mTOR (1:1000, Cell Signaling Technology, 2983T, MA, United States), HSP90AA1 (1:250, ABclonal, A23880, Wuhan, China), TNF- α (1:1000, ABclonal, A0277, Wuhan, China), p- IKKβ (Ser177/181, 1:1000, Cell Signaling Technology, 2694T, MA, United States), IKKβ (1:1000, Cell Signaling Technology, 2678T, MA, United States), IL- 6 (1:1000, ABclonal, A0286, Wuhan, China), NFκB (1:5000, Abmart, T55034S, Shanghai, China), p- NF- κB (Ser536,1:1000, Cell Signaling Technology, 3033T, MA, United States), MyHC (1 μg/mL, R&D Systems, CAEI0822101, MN, United States), Atrogin1 (1:1000, Abways, CY8766, Shanghai, China) and MuRF1 (1:1000, Proteintech, 55 456- 1- AP, Wuhan, China), and then, an ECL plus kit was used to produce the blots (Proteintech, Wuhan, China).

Techniques: Western Blot, Expressing